검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | HER2-targeted Therapy |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting HER2-associated antigen |
MoA Biomarker | HER2-low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies.. Despite the success of HER2-targeted antibody-drug conjugates (ADCs) in common cancers, there is a lack of real-world evidence regarding their role in rare tumors where ERBB2 gene amplification by next-generation sequencing (NGS) may serve as a more precise driver than traditional protein exp… |
Clinical Primary efficacy | ORR 18.75% |
Clinical ORR | 18.75% |
Clinical Result source | ClinicalTrials.gov NCT00622466 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | HER2-targeted Therapy |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting HER2-associated antigen |
MoA Biomarker | HER2-low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies.. Despite the success of HER2-targeted antibody-drug conjugates (ADCs) in common cancers, there is a lack of real-world evidence regarding their role in rare tumors where ERBB2 gene amplification by next-generation sequencing (NGS) may serve as a more precise driver than traditional protein exp… |
Clinical Primary efficacy | ORR 18.75% |
Clinical ORR | 18.75% |
Clinical Result source | ClinicalTrials.gov NCT00622466 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교